GLP-1 Aging Clocks at ARDD 2026: What Novo Nordisk and Eli Lilly Actually Reported (9 October 2026)

What Happened at ARDD 2026?

The Aging Research and Drug Discovery (ARDD) meeting in Boston this autumn gave GLP-1 pharmacology an unusually prominent slot. Trade reporting describes both Novo Nordisk and Eli Lilly presenting early analyses that use molecular “aging clocks” on samples from their incretin-class programmes.[1][2] MIT Technology Review’s coverage on 6 October 2026 framed the claim as the drugmakers saying that clock readouts moved in a favourable direction for treated participants.[3]

This guide sets out what was reported, who said it, and the limits of the evidence. It is a summary of third-party reporting dated 9 October 2026; we have not seen the underlying slides or data, and we make no claim about any research-use reagent.

What Is an Aging Clock, and Which Types Were Used?

An aging clock is a model that estimates a biological-age value from molecular measurements. Two families matter here. Epigenetic clocks read DNA-methylation patterns, and proteomic clocks read panels of circulating proteins. According to MIT Technology Review, Novo’s work used proteomic clocks while Lilly’s tirzepatide study used epigenetic clocks.[3]

The distinction is not cosmetic. The same participant can look different across clock types, and the reporting notes that the size of the difference varied with both the clock and the organ system examined.[3] Clocks are research biomarkers: none has been accepted by a regulator as a surrogate for lifespan or disease outcome.

What Did Novo Nordisk Report?

Per Longevity.Technology’s conference coverage, Nikolaj Roed presented two strands of semaglutide analysis. The first was modelling that applied SELECT-trial effect estimates to a UK real-world semaglutide cohort (n=19,117), projecting about 1.9 additional years of remaining life overall. This is a projection from assumptions, not an observed survival result.[2]

The second was a blood-protein analysis across five placebo-controlled semaglutide trials, including SELECT and FLOW, reported as covering 10,052 people with follow-up of up to 156 weeks. Lower proteomic biological-age estimates were reported from roughly 13–20 weeks, with the difference sustained or larger by week 150. The work is described as a Research Square preprint, which means it has not been peer reviewed.[2] MIT Technology Review reports the overall gap as roughly two to three years on the proteomic measure.[3]

What Did Eli Lilly Report?

Lilly’s contribution was thinner in the coverage we could find. MIT Technology Review describes a smaller tirzepatide study using epigenetic clocks in which molecular time mostly advanced more slowly in treated participants.[3] Longevity.Technology adds that Lilly showed early, unpublished work on validating healthspan-related measures for GLP-1s.[2] We could not locate sample sizes or effect sizes for the Lilly analysis, so none are given here.

Retatrutide, Lilly’s investigational GIP/GLP-1/glucagon triple agonist, was not reported as part of these clock analyses. Readers following that programme should use our retatrutide overview and research-grade retatrutide page for receptor pharmacology and reagent specifications only.

Why Is This Not Evidence of Slower Human Aging?

Four limits apply. First, none of the 2026 ARDD material had appeared in a peer-reviewed journal at the time of reporting. Second, the outputs are estimates derived from biomarker models rather than measured lifespan or disease-free survival. Third, GLP-1 treatment changes body composition and inflammatory and metabolic markers that many clocks are known to respond to, so a clock shift may partly reflect those changes rather than any separate process. Fourth, the sponsors chose the analyses presented.

Steve Horvath, a UCLA professor credited with inventing epigenetic clocks, was quoted as calling the roughly two-year effect strong while saying more evidence is needed before these drugs can be described as geroprotectors.[3] An FDA clinical pharmacologist at the meeting reportedly put the regulator’s role as that of referee rather than coach, a reminder that no aging indication exists to be approved.[2]

How Does This Compare With the Peer-Reviewed Epigenetic Trial?

The better-controlled datapoint remains the May 2026 Nature Communications randomised trial of semaglutide in 84 adults with HIV-associated lipohypertrophy, which reported shifts in several epigenetic clocks over 32 weeks.[4] We cover it in our semaglutide epigenetic aging guide and the broader GLP-1 epigenetic aging summary. That trial is peer-reviewed but small and population-specific; the ARDD analyses are larger in scope but unpublished. Neither answers the lifespan question.

What Should Researchers Watch For Next?

Three developments would change the weight of this evidence. A peer-reviewed publication of the Novo proteomic analysis would allow the methods, clock selection and pre-specification to be checked, and the Research Square preprint would need to survive journal review. Disclosure of the Lilly tirzepatide sample size, comparator and clock definitions would let readers judge whether the favourable direction is robust or an artefact of one clock family. Finally, independent replication outside sponsor-run studies would test whether the clock shifts track anything beyond the metabolic and body-composition changes already documented for these drugs.

Until then, the defensible reading is narrow: two sponsors reported biomarker-clock differences at a scientific meeting, and sceptical specialists have asked for more data. For earlier context on how the GLP-1 class is studied in the lab, see the peptide research landscape 2026 overview.

How Should Researchers Separate Pharma Data from Research-Use Reagents?

Everything above concerns licensed or sponsor-developed pharmaceutical products studied under regulatory oversight. Research-grade peptides are a different category of material: they have no clinical programme and no claim to equivalence with a sponsor’s product. Velox Peptides supplies them solely as HPLC-verified reagents for in vitro work, with batch documentation on request. Not for human or veterinary use. Browse the metabolic research reagents for catalogue specifications.

Frequently Asked Questions